StockVS

纳斯达克 · USD

Aclarion, Inc. (ACONW) 股票分析

Aclarion, Inc.(ACONW)是在纳斯达克上市的股票,以美元交易。

ACONW

$0.05

+$0.01 (+23.75%)

2026年9月3日 · 收盘

这是一只衍生品——Aclarion, Inc.(ACON)普通股的认股权证。

发行人的基本面数据显示在发行人页面,而非本页。

查看ACON →

价格走势

悬停查看每日收盘价。虚线表示区间起始价。

ACONW 关键统计数据

数据截至2026年9月3日
交易
开盘价
$0.05
前收盘价
$0.04
当日波动区间
0.03–0.05
52周波动区间
0.03–0.05
成交量
5.66K
Beta系数股价相对大盘的波动幅度。1.0与大盘同步,高于1.0波动更大,低于1.0更小。
1.24

仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。

ACONW 历年回报率

历年回报率根据每日收盘价计算。 不完整年度以浅色显示并标有星号。

年份回报率
2026 (不完整年度)+10.49%
2025 (不完整年度)+0.00%

数据截至2026年9月3日。

关于Aclarion, Inc.

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

公司简介以英文显示。

访问官网 →